Biogen

News

Biogen exits biosimilar JV with Samsung, raising $2.3bn

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation.

News

Closeup of X-ray photography of human brain

Biogen tweaks confirmatory trial of Alzheimer's drug Aduhelm

Biogen and Eisai have expanded the size of the confirmatory trial of their Alzheimer's drug Aduhelm in order to "strengthen the data" for the drug.

News

Medicare limits Aduhelm coverage to clinical trial participa...

Biogen's difficult launch of controversial Alzheimer's therapy Aduhelm has been made even harder by a proposal by Medicare to cover the drug only for certain patients enrolled in clinical t

News

Biogen looks beyond Spinraza in SMA with Ionis deal

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

News

Biogen, Eisai Alzheimer's drug lecanemab fast tracked by FDA

Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer's programmes, as the FDA awards a fast-track designation to lecanemab, their follow-up t

News

Japan looks set to follow EU in rejecting Alzheimer's drug A...

The Japanese regulator looks like it could follow the European Commission and reject approval of Biogen and Eisai's Alzheimer's disease therapy Aduhelm, leaving the FDA an outlier in its st

Biogen exits biosimilar JV with Samsung, raising $2.3bn

Biogen tweaks confirmatory trial of Alzheimer's drug Aduhelm

Medicare limits Aduhelm coverage to clinical trial participa...

Biogen looks beyond Spinraza in SMA with Ionis deal

Biogen, Eisai Alzheimer's drug lecanemab fast tracked by FDA

Japan looks set to follow EU in rejecting Alzheimer's drug A...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Biogen

Editor's Picks